Moderna, a new generation of transformative medicines for patients, today announced a supply agreement with the UK government to supply mRNA-1273, its Covid-19 vaccine candidate, beginning in March 2021 if it is approved for use by UK regulatory authorities.
Mylan and Pfizer announced that the U.S. Federal Trade Commission (the “FTC”) accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business.
Cheplapharm Arzneimittel has agreed to acquire commercial rights of heart failure and hypertension drugs from AstraZeneca in a deal valued at around $400m.
Eli Lilly has secured a $375m contract from the US government to supply 300,000 doses of its bamlanivimab (LY-CoV555) 700mg investigational neutralising antibody to fight against Covid-19.
GlaxoSmithKline (GSK) and Sanofi have entered into a statement of intent with Gavi to supply 200 million doses of their adjuvanted recombinant protein-based Covid-19 vaccine to the COVAX Facility.
Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support the Ministry’s ongoing efforts to secure early access to a safe and effective COVID-19 vaccine for the people of Qatar.
JSR Life Sciences is set to expand European gene-to-GMP biologics manufacturing facilities of its affiliate companies KBI Biopharma and Selexis in Geneva, Switzerland.
Vifor Pharma has entered into a licence agreement with Cara Therapeutics to commercialise Korsuva (difelikefalin) to treat chronic kidney disease-associated pruritus (CKD-aP) in the US.
The World Bank has sanctioned a package of $12bn for developing nations towards the purchase and distribution of Covid-19 vaccines, treatments, and tests.
European Commission (EC) has approved an advance purchase agreement under which Janssen Pharmaceutical Companies will supply up to 400 million doses of its Covid-19 vaccine candidate.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.